Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
about
PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders.The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialCholestatic liver diseases: new targets, new therapies
P2860
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@en
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@nl
type
label
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@en
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@nl
prefLabel
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@en
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@nl
P2093
P50
P1476
Seladelpar (MBX-8025), a selec ...... ase 2, proof-of-concept study.
@en
P2093
Alexandra Steinberg
Andreas E Kremer
Bradley L Freilich
Bruce R Bacon
Charles A McWherter
Christopher L Bowlus
Cynthia Levy
David E Bernstein
David Jones
Fedja Rochling
P304
P356
10.1016/S2468-1253(17)30246-7
P577
2017-08-14T00:00:00Z